GlassScriptPhysician profile
Pamela Lupo
NPI 1346578697
$1,602.59
in general payments reported to CMS, 2019-2025
16 companies · $137 in 2025
The $137 reported for 2025 was more than what a typical Neurodevelopmental Disabilities (Pediatrics) provider received nationally (typical 2025 total: $136).
See the full distribution for Neurodevelopmental Disabilities (Pediatrics)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.83 · 2021: $11.52 · 2023: $700 · 2024: $735 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,510 · Education: $62.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,510.24 |
| Education | $62.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $720.44 | 2023-2025 | Fintepla, Briviact, Nayzilam |
| Supernus Pharmaceuticals, INC. | $224.15 | 2023-2024 | Qelbree |
| Jazz Pharmaceuticals INC. | $116.62 | 2023-2024 | |
| Immedica Pharma US, INC. | $83.11 | 2023-2024 | |
| Livanova USA, INC. | $76.50 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Springworks Therapeutics, INC. | $75.52 | 2024-2025 | Gomekli |
| Sk Life Science, INC. | $57.54 | 2023-2024 | |
| Acadia Pharmaceuticals INC | $55.86 | 2023 | Daybue |
| Abbvie INC. | $39.72 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $26.96 | 2023 | Acthar |
| Biomarin Pharmaceutical INC. | $26.06 | 2021-2023 | Brineura |
| Otter Pharmaceuticals, LLC | $24.37 | 2024 | Sympazan |
| Ironshore Pharmaceuticals INC. | $24.20 | 2023 | Jornay Pm |
| Greenwich Biosciences, INC. | $18.83 | 2019 | |
| Tris Pharma INC | $17.49 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $15.22 | 2024 | Skyclarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Lupo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.